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Summary The efficacy of high-dose intramuscular MPA therapy in controlling progressive measurable
metastatic breast carcinoma was assessed in 32 women. In addition serial measurements of MPA blood levels
were carried out in 20 of the patients and subjective effects of treatment were monitored in detail in 18 of the
women. Overall 6 patients (19%) gained an objective response and a further 7 (22%) experienced disease
stasis from 4-17 months whilst on treatment. Significant differences in serum MPA levels were seen between
responders and non-responders, objective tumour shrinkage only being seen in those patients who rapidly
attained, and sustained, blood levels in excess of 100ngml-1. Subjective assessment showed no evidence of a
euphoriant effect of MPA therapy in the non-responders group.
Reports of high-dose Medroxyprogesterone acetate
(MPA) administration in the treatment of advanced
breast cancer began to appear in the mid 1970s and
in 1979 a review of the published data concluded
that an objective remission rate of 40% was seen in
women who had not previously received cytotoxic
therapy (Ganzina, 1979). In addition to objective
benefit the relative lack of toxicity of MPA
combined with its ability to relieve pain (Pannuti et
al., 1979), improve performance status (Ganzia,
1979), and increase appetite and body weight
(Cavalli et al., 1983) led to the view that treatment
carried a significant subjective benefit. Clinical trials
showed that daily intramuscular doses of MPA of
500mg or more were necessary for a significant
incidence of response (Ganzina, 1979), but
pharmacokinetic studies have indicated considerable
differences in bioavailability between patients
(Salimtschik et al., 1980). The present study set out
across the objective response to high-dose MPA in
women with advanced breast cancer and also to
monitor both serum MPA levels and subjective
effects of treatment in order to identify any
correlations between these three parameters.
Materials and methods
The study was designed as an open, single group
assessment and women with evaluable, progressing,
locally recurrent or metastatic carcinoma of the
breast which had failed to respond to, or relapsed
after, conventional therapy were enrolled.
Medroxyperogesterone acetate (Farlutal,
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Farmitalia Carlo Erba, 500mg in 2.5ml.
suspension) was administered by deep i.m. injection
into the gluteal region at a dose of 500mg for 28
days. This induction phase was followed by
maintenance therapy of 1000mg i.m. once weekly.
The majority of patients received treatment on an
outpatient basis, injections being given by the
District Nurse.
Pre-treatment assessment included a full physical
examination, blood count, biochemical profile,
chest X-ray and liver and bone isotope scans.
Blood tests were repeated weekly during the
induction phase and monthly thereafter. Other
investigations were repeated when needed to assess
response.
Objectives response was assessed at monthly
intervals and UICC criteria were adopted (Hayward
et al., 1977). Complete response indicated
disappearance of all known disease and partial
response was a >50% decrease in measurable
lesions and objective improvement in evaluable but
non-measurable lesions, with no new lesions and no
progressions of existing lesions. Those patients
whose lesions decreased by <50% or increased by
<25% were considered to have disease stasis. The
UICC criteria do not specify a minimum duration
in order for such regressions to be considered a
response, but in the present study only those
patients in whom remission or stasis was sustained
for more than 3 months from the time of starting
MPA were included in these categories.
Subjective response was monitored with a
preliminary questionnaire prepared by the
European Organisation for Research and
Treatment of Cancer (EORTC) Study Group on
Quality of Life. This was a verbal self-rating scale
made up of 36 questions, 12 relating to purely
© The Macmillan Press Ltd., 1984364 J.R. JOHNSON et al.
physical parameters, two groups of 10 and 12
questions respectively examining positive and
negative aspects ofmood and the last two questions
aimed at a global assessment of the patient's
feelings. The development and validation of the
questionnaire has been described elsewhere (Linssen
et al., 1982; Stewart & van Dam, 1983) but it has
not previously been used to prospectively monitor
the subjective effects of a specific treatment.
Questionnaires were completed before treatment, at
weekly intervals during the induction phase and
monthly thereafter for a total of three months.
Medroxyprogesterone acetate levels were
measured in the serum samples by radioimmuno-
assay (Shrimanker et al., 1978), blood being taken
before treatment, weekly during induction and
monthly thereafter. Following venepuncture the
blood was allowed to clot and the serum separated
and stored at -20° until analysed. The intra-assay
variation was <10% and the inter-assay variation
<15%. The specificity of the assay has been
previously reported as >80% (Mathrubutham &
Fotherby, 1981) and in the present series most
samples were completely specific with - 30% of the
specimens showing small amounts (always <20%)
of other material reacting with the antiserum.
Results
Thirty-two women entered the study, two died from
rapidly progressive disease before completion of
induction therapy, but have been included in the
overall analysis. All patients had received extensive
prior therapy (surgery in 24 cases, radiotherapy in
28, cytotoxic drugs in 23, tamoxifen in 31, other
hormones in 15 and interferon in 3). The mean age
of the group was 63 years (range 37-76) and all
patients were post-menopausal.
Six patients (19%) had an objective response to
treatment with 3 complete and 3 partial remissions.
Details of the response rate for individual sites of
disease are given in Table I. The mean duration of
response was 12 months (range 8-16+), measured
from the time of commencing MPA. One patient
died at 14 months from other causes whilst still in
Table I Response by site
CR PR No change Progression
Soft tissue
breast (n= 13) - - 6 7
cutaneous (n=26) 4 2 9 11
nodes (n==20) 3 4 6 7
Bone(n=13) - 1 3 9
Lung (n=9) - 1 8
Liver (n =4) - -
remission and two others remain in remission at 9
and 16 months respectively. A further 7 women
(22%) experienced disease stasis whilst receiving
MPA. The average duration of stasis was 12
months (range 4-17).
Data on MPA plasma levels were available for 20
patients (5 of whom had objective response, 4
disease stasis and 11 progressive disease). In
responders there was a rapid rise in blood levels to
above 150ngml1 by the end of the induction
period whereas the remaining patients had an
average level ofonly 70ngml-P at this time (Figure
1). The difference in values between responders and
the disease-stasis/progression group was statistically
significant (Student t test) at all time points up to
12 weeks after commencing treatment (Table II).
By this stage most of the non-responders had come
off treatment, by 20 weeks all four of the disease-






Figure 1 Title: Mean MPA blood level and response.
Scores for subjective assessment over the first 3
months of treatment were available for 5 patients
who showed an objective response and 13 with
progressive disease. A preliminary analysis showed
a tendency for the overall scores for the responders
to increase during treatment whereas those of the
non-responders declined (Priestman, 1984). These
global scores included a wide variety of factors and,
in order to address the question of whether there
was any euphoriant effect from the MPA therapy
apparent in the non-responders, the nine
parameters on the questionnaire specifically relating
to the patient's feeling of well-being were analysed
separately. (These were irritability, worry,HIGH-DOSE MPA IN ADVANCED BREAST CANCER 365
Table II MPA serum levels and response
MPA serum level ngml-
(mean & s.d.)
responders (n=5)
Time non-responders & Significance
weeks stasis (n=13) P
0 0 0
1 45+30 17+12 (13)a <0.05
2 76+32 40+23 (13) <0.05
3 111+26 57+28 (13) <0.05
4 153+21 69+30 (13) <0.01
8 125+37 77+38 (11) <0.05
12 135+43 88+27 (7) NS
16 158+49 107+23 (6) NS
aFigures in parenthesis give number of patients.
The decline in numbers after 4 weeks is due to
non-responders coming off treatment.
depression, anxiety, tension and four questions on
general mood and feelings).
The results are shown in Figure 2 and, although
scores for responders rise initially (indicating
improved wellbeing) whilst the non-responders
scores remain essentially static, there is no
statistical difference between the two groups at any











Figure 2 Title: Scores for well-being during MPA
treatment.
Twenty-two patients experienced side effects
during treatment and in three these were of
sufficient severity to stop treatment (Table III). The
elevation of haemoglobin was greater than
1 mgdl-I in 15 patients and in 7 of these it was
>2mgdl'- but no symptoms resulted from this
increase. The syndrome of trembling with or
without muscle cramps and sweating usually only
appeared after 2 to 3 months therapy and was mild
in 6, moderate in 3 and severe in 3 cases. All but
Table III Side effects ofhigh-dose MPA
Haemoglobin increase 22 patients (47%)
Trembling/muscle cramps/
sweating 12 patients (38%)
Weight gain 7 patients (22%)
Cushingoid facies 4 patients (13%)
Gluteal abscess 1 patient (3%)
one of the patients with moderate or severe
symptoms had plasma MPA levels greater than
130ngml-1, and in all instances symptoms
disappeared following reduction in MPA dose.
Seven patients had an increase of more than 5% of
their pre-treatment body weight, a further 11 had
smaller weight gains. One patient developed central
chest pain after 6 months of treatment and an ECG
confirmed myocardial infarction, whilst a second
had increased frequency ofpreviously noted anginal
attacks. One patient became myxoedematous during
treatment but another, who was on treatment for
hypothyroidism, found her thyroxine requirement
to be halved. In one patient who developed a
gluteal abscess at the injection site, this was
sufficiently severe to necessitate admission to
hospital for intensive supportive care.
Discussion
Previous studies of high-dose MPA in advanced
breast cancer have reported response rates ranging from 28% (Mattson, 1978) to 46% (Pannuti et al., 1979) in patients who had not previously received
cytotoxic therapy and this figure has risen to over
70% when patients were selected according to
oestrogen-receptor status (Mattson, 1980). In
comparison with these figures the results in the
present series are, at first sight, somewhat
disappointing, but this lower response rate is
probably due to the heavy pre-treatment of the
patients reflecting a more advanced stage of disease.
Previous evaluations of high-dose MPA have
commented on the beneficial effects on bone
metastases with objective response rates in excess of
50% being reported in patients with skeletal
secondaries (Pannuti et al., 1979; Robustelli della
Cuna et al., 1978) whereas in this series only 1/13 patients with bone involvement gained objective benefit. All previous series have commented on the higher response rate seen in soft tissue recurrence as
compared with visceral secondaries and the present results reinforce this observation. When responses did occur, however, they were of worthwhile duration and the induction of disease stasis in 21% of patients for an average of 12 months should
probably also be considered a therapeutic advantage.366 J.R. JOHNSON et al.
There was no relationship between MPA serum
levels and race, body weight or liver function.
Within one week of commencing therapy the
responders had reached significantly higher serum
levels than the remaining patients and their values
remained significantly higher up to 16 weeks.
Interpretation of the levels at and beyond this time
is obscured by dose reductions, due to toxicity, and
the fall off in the numbers of non-responders due
to patients coming off treatment because of
progressive disease. The shape of the curves for the
two patient groups suggests that the responders
may have been slower metabolisers of MPA, thus
rapidly achieving high blood levels, and the
possibility of there being different patterns of MPA
metabolism which might be of therapeutic
significance merits further investigation.
A universally accepted and completely validated
system for monitoring subjective response has still
to be defined and it would probably be premature
to consider the results of any such analysis as
conclusive. Given this caveat it was still considered
important to try to identify whether MPA therapy
was associated with a euphoriant effect. For this
reason only these aspects of the EORTC
questionnaire relating specifically to mood and
well-being have been considered in the present
analysis, excluding those parameters relating to
physical status, symptoms of disease and side-
effects of therapy. On the basis of the data
presented here no improvement in well-being could
be identified in the non-responders and only a
minimal transient benefit was recorded among
those who showed objective regression of disease.
All the side effects seen in the present study have
been reported previously. The significance of
cardiovascular complications (myocardial infarction
and increased frequency of anginal attacks) in two
patients, and changes in thyroid function in two
further women, remains to be determined with
relation to MPA therapy. Compliance was not a
problem and treatment was generally carried out on
an outpatient basis, injections being given by the
District Nurse. Although one patient did develop a
severe gluteal abscess, this was only one case in a
series involving over 1500 injections.
These results indicate that MPA has useful
activity in either arresting disease progression or
bringing about objective remission of worthwhile
duration in women with end-stage breast
carcinoma.
We would like to thank Ms Pamela Perry of Farmitalia
Carlo Erba for her help in establishing this study and for
providing the Farlutal.
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